2'-Nor-2'-deoxyguanosine

  • 2-Amino-1,9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6-h-purin-6-one
  • Gancyclovir
  • BE-759
  • Vitrasert
  • Hydroxyacyclovir
  • Cymevan
Formula
C9H13N5O4
Structure
Description
Crystals from methanol.
Uses
Medication.

Registry Numbers and Inventories.
CAS
82410-32-0
RTECS
MF8407000
RTECS class
Drug; Mutagen
Merck
12,4374
Beilstein/Gmelin
3654487

Properties.
Formula
C9H13N5O4
Formula mass
255.23
Melting point, °C
250
Solubility in water
Very soluble
pKa/pKb
9.15 (pKa)
Partition coefficient, pKow
-2.07
Heat of fusion
37.9 kJ/mol

Hazards and Protection.
Storage
Keep in a cool, dry, dark location in a tightly sealed container or cylinder. Keep away from incompatible materials, ignition sources and untrained individuals. Secure and label area. Protect containers/cylinders from physical damage.
Handling
All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood.
Protection
Chemical splash goggles in compliance with OSHA regulations are advised; however, OSHA regulations also permit other type safety glasses. Whre chemical resistant gloves. To prevent repeated or prolonged skin contact, wear impervious clothing and boots.
Respirators
Use NIOSH/MSHA approved respirator appropriate for exposure of concern.
Small spills/leaks
Evacuate area and ventilate. Wear protective equipment. If required, use an inert absrobent. Sweep up and place in an appropriate container for disposal. Wash contaminated surfaces.
Stability
Exposure to temperatures exceeding 40 C should be avoided. When stored as directed, the sterile powder has an expiration date of 3 years following the date of manufacture.
Incompatibilities
Strong oxidizing agents.

Fire.
Fire fighting
Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use agent most appropriate to extinguish fire.

Health.
Carcinogin
CP65
Exposure effects
Fever has occurred with ganciclovir therapy. neuropathy and paresthesia have occurred during clinical trials with immunocompromised patients. Seizures associated with ganciclovir use have also occurred. Ganciclovir is classified by the manufacturer as US FDA pregnancy category C.
   Ingestion
Vomiting, diarrhea, and anorexia have been reported in clinical trials. Upper gastrointestinal bleeding has occurred following ganciclovir therapy.
   Inhalation
Pneumonia, dyspnea, and cough have been reported with ganciclovir.
   Skin
Pruritus, rash, and sweating were the most frequent dermatologic complaints associated with intravenous or oral ganciclovir.

First aid
 
   Ingestion
Seek medical attention. If individual is drowsy or unconscious, do not give anything by mouth; place individual on the left side with the head down. Contact a physician, medical facility, or poison control center for advice about whether to induce vomiting. If possible, do not leave individual unattended.
   Inhalation
If symptoms develop, move individual away from exposure and into fresh air. If symptoms persist, seek medical attention. If breathing is difficult, administer oxygen. Keep person warm and quiet; seek immediate medical attention.
   Skin
Flush skin with plenty of soap and water for at least 15 minutes while removing contaminated clothing and shoes.
   Eyes
Manufacturer recommendations include caution in handling ganciclovir formulations (intravenous {alkaline ph 11} or oral) and to avoid direct contact with skin or mucous membranes.

Transport.